NP Medical News about methamphetamine clinical pharmacology

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A review of the clinical pharmacology of methamphetamine
Addiction, 06/29/09

Cruickshank CC et al. - Repeated use may induce neurotoxicity, associated with prolonged psychiatric symptoms, cognitive impairment and an increased risk of developing Parkinson's disease. Abrupt cessation of repeated methamphetamine use leads to a withdrawal syndrome consisting of depressed mood, anxiety and sleep disturbance.

Methods

Relevant literature was identified through a PubMed search.
Additional literature was obtained from relevant books and monographs.

Results

The mean elimination half-life for methamphetamine is approximately 10 hours, with considerable inter-individual variability in pharmacokinetics.
Direct effects at low-to-moderate methamphetamine doses (5-30 mg) include arousal, positive mood, cardiac stimulation and acute improvement in cognitive domains such as attention and psychomotor coordination.
At higher doses used typically by illicit users (≥50 mg), methamphetamine can produce psychosis.
Its hypertensive effect can produce a number of acute and chronic cardiovascular complications.
Acute withdrawal lasts typically for 7-10 days, and residual symptoms associated with neurotoxicity may persist for several months.

<< Previous
Effects of salt supplementation on the albuminuric response to...

Next >>
Intravenous diltiazem is superior to intravenous amiodarone or...